Merck & Co. Faces Q3 Earnings Downgrade: What Investors Need to Know
Leerink Partners has cast a shadow on Merck & Co.’s third-quarter 2025 earnings outlook, signaling a notable adjustment in their financial projections for the pharmaceutical giant. This…
UnitedHealth Group Q3 Earnings: Leerink Partners Downgrades Forecast
Leerink Partners, a prominent research firm, has issued a stark negative outlook for UnitedHealth Group’s (NYSE:UNH) Q3 2025 earnings, significantly lowering their earnings per share (EPS) estimates….
Leerink Partners Boosts Repligen Earnings Forecast: Biotech Stock Outlook
The biotechnology sector is abuzz with the latest financial projections for Repligen Corporation, as leading investment analysts at Leerink Partners have revised their earnings estimates upward for…